Health
Drug Repurposing in Cancer Treatment: Emerging Strategies and Promising Developments
Cancer continues to be one of the leading causes of death globally, with millions of new diagnoses each year. The conventional process of developing new cancer drugs is notoriously slow and costly, often requiring more than a decade and billions of dollars to reach patients. In response, drug repurposing, also called drug repositioning, has gained significant attention as a practical alternative. This strategy finds new anticancer applications for medications already approved for other medical conditions. Because these drugs have established safety records, known dosing guidelines, and existing production methods, repurposing can dramatically shorten development timelines and lower financial barriers compared with creating entirely new compounds. Organizations focused on innovative and integrative oncology approaches, such as Sanare Lab, offer valuable insights and resources for exploring experimental protocols in this rapidly evolving field.
One especially interesting avenue within drug repurposing is methylene blue cancer research. This compound, long used as a dye and as a treatment for methemoglobinemia, is now under investigation for possible anticancer effects. Researchers have examined methylene blue in photodynamic therapy, where it serves as a photosensitizer. When activated by specific wavelengths of light, it generates reactive oxygen species that can damage and kill cancer cells. Laboratory and animal studies have shown reductions in tumor volume in models of colorectal cancer, breast cancer, and melanoma, particularly when combined with other treatment approaches. These findings illustrate how a familiar, inexpensive compound might provide new ways to target resistant or difficult-to-treat tumors.
Why Drug Repurposing Matters in Oncology
The main advantage of repurposing lies in its efficiency. Traditional drug discovery begins with identifying a new molecule, followed by years of laboratory testing, animal studies, and multi-phase human trials to confirm both safety and effectiveness. Repurposed drugs skip much of this early work because regulators have already approved them for their original use. Investigators can therefore move more quickly to testing whether the drug works against cancer, often starting directly in mid- or late-stage clinical trials.
Cost is another critical factor. The failure rate in new oncology drug development frequently exceeds ninety percent, driving up expenses that are eventually reflected in treatment prices. Many repurposed candidates are off-patent generics, which means they can be produced and distributed at a fraction of the cost of branded medicines. With cancer rates expected to keep rising worldwide, especially in low- and middle-income countries, affordable options derived from existing drugs could help close gaps in access to effective care.
Well-Known Examples of Repurposed Drugs in Cancer
Drug repurposing already has several important successes in oncology. Thalidomide, originally marketed as a sedative and later withdrawn because of severe birth defects, was rediscovered in the late 1990s for multiple myeloma. Its ability to block new blood vessel formation in tumors made it a valuable addition to treatment regimens, and it remains widely used today, frequently combined with other agents.
All-trans retinoic acid, first studied for skin conditions, transformed outcomes in acute promyelocytic leukemia by prompting malignant cells to mature into normal ones. When paired with arsenic trioxide, another agent with a long history in traditional medicine, the combination now achieves very high remission rates in this once-deadly subtype of leukemia.
Metformin, the most commonly prescribed medication for type 2 diabetes, has attracted attention after population studies showed lower cancer rates among diabetic patients taking it. The drug appears to interfere with energy metabolism in cancer cells by activating a key regulatory pathway that slows uncontrolled growth. Multiple clinical trials have tested metformin as an add-on to standard chemotherapy or radiation in breast, prostate, colorectal, and other cancers, with some studies reporting improved survival or reduced recurrence.
Statins, best known for lowering cholesterol, have also been evaluated for anticancer effects. By blocking an enzyme involved in cholesterol synthesis, they disrupt signaling pathways that cancer cells use to grow and spread. Large observational studies have linked statin use to modestly reduced risk of certain cancers, and ongoing research continues to explore their role as adjunctive therapy.
Other candidates include antiparasitic agents such as mebendazole, which interfere with the structural framework cancer cells need to divide, and the anticonvulsant valproic acid, which modifies gene expression by inhibiting enzymes that control DNA packaging. Both have shown activity in laboratory models of colorectal, brain, and pancreatic cancers, and early human studies are underway.
Spotlight on Methylene Blue in Cancer Research
Returning to methylene blue, this compound continues to generate interest because of its diverse biological effects. Beyond its role in photodynamic therapy, methylene blue can influence cancer cell metabolism. Many tumors depend heavily on glycolysis for energy production even when oxygen is available, a phenomenon known as the Warburg effect. Methylene blue appears to disrupt this altered metabolism, potentially starving cancer cells of fuel. In preclinical models of ovarian cancer, particularly those resistant to platinum-based chemotherapy, methylene blue slowed tumor progression more effectively than standard drugs in some experiments.
When used in photodynamic therapy, methylene blue tends to concentrate in mitochondria, the energy-producing structures inside cells. Light exposure then triggers the release of damaging oxygen radicals, leading to cell death through apoptosis. Systematic reviews of animal studies have reported consistent tumor shrinkage across several cancer types, including breast carcinoma and skin melanoma, often with low toxicity at the doses tested.
Methylene blue may also improve tumor oxygenation, which could make radiotherapy more effective. Poorly oxygenated regions within solid tumors are notoriously resistant to radiation, so any agent that increases oxygen availability has therapeutic potential. In addition, surgeons sometimes use methylene blue injections to map sentinel lymph nodes during breast cancer operations, helping to identify the first nodes where cancer is most likely to spread.
Despite these encouraging signals, methylene blue remains experimental for most cancer applications. While side effects are generally mild at therapeutic doses, interactions with certain medications require careful monitoring. Large, well-controlled clinical trials are still needed to determine whether the promising laboratory and early human data translate into meaningful benefits for patients.
Remaining Challenges and the Path Forward
Drug repurposing is not without obstacles. Because many candidate drugs are generic, pharmaceutical companies have limited financial incentive to fund expensive trials for new indications. Regulatory agencies sometimes require nearly as much evidence for a repurposed use as for a completely novel drug, which can slow progress. Off-label prescribing also raises questions about informed consent and standardized protocols when robust data are lacking.
Collaborative efforts are helping to address these barriers. Networks of researchers, clinicians, and advocacy groups are systematically reviewing existing drugs for anticancer potential, prioritizing those with the strongest preclinical rationale, and pushing for well-designed trials. Advances in computational biology allow scientists to screen thousands of compounds against cancer-related targets much faster than before, narrowing the list of drugs worth testing in the laboratory or clinic.
Looking ahead, combination strategies are likely to dominate. Pairing repurposed agents with immunotherapy, targeted therapies, or conventional chemotherapy could produce synergistic effects greater than any single treatment alone. Personalized approaches that match specific drugs to the molecular features of an individual’s tumor will further refine their use.
In summary, drug repurposing offers a realistic and increasingly important strategy for improving cancer care. From established successes like thalidomide and metformin to emerging candidates such as methylene blue, the field demonstrates that familiar medicines can sometimes deliver unexpected benefits against one of medicine’s toughest challenges. Sustained investment in rigorous clinical research and broader collaboration will determine how much further this approach can take us toward more effective, accessible treatments for patients everywhere.
Health
More Europeans Take Up Sport, but Major Gaps Remain Across Countries
More Europeans are exercising regularly than they were four years ago, but participation continues to vary sharply depending on where people live, their age, education and financial circumstances, according to a new European Commission survey.
The latest Eurobarometer survey on sport and physical activity found that 39% of respondents said they never exercise or play sport, down from 45% in 2022. Nearly half of the 26,508 people surveyed said they exercise or play sport every day or several times a week.
The results also showed wide differences between countries. Finland recorded the highest share of people exercising daily, at 21%, followed by Denmark at 20%. In both countries, another 59% of respondents said they exercise several times a week.
At the other end of the scale, 68% of respondents in Portugal said they never exercise or play sport. Greece and Romania followed, with 66% in each country reporting that they never take part in sport or exercise.
Time was the most commonly cited barrier among people who wanted to exercise more, with 37% identifying it as an obstacle. A lack of motivation or interest was mentioned by 26%, while 15% pointed to health problems or injury. Cost was cited by 12%.
Education and household finances were also closely linked to participation. Some 59% of people who continued their education until at least the age of 20 said they exercise or play sport several times a week. That compared with 23% among those who left education at 15 or younger.
Financial circumstances showed a similar divide. People who said they had the greatest difficulty paying their bills were twice as likely to report never exercising as those who rarely or never faced financial difficulties, at 54% compared with 26%.
“More Europeans are getting active, but the opportunity to take part still depends too much on income, age and education,” said Roxana Mînzatu, Executive Vice-President for Social Rights and Skills, Quality Jobs and Preparedness.
The survey also highlighted a significant age gap. Nearly three-quarters of people aged 15 to 24 exercise or play sport at least several times a week, compared with 25% of those aged 75 and over. Health problems or injury were the main barrier for older respondents, while younger and middle-aged people were more likely to cite a lack of time.
Physical activity linked to everyday life also increased. Active commuting rose from 24% in 2022 to 37%, while 72% of respondents said they now walk for at least 10 minutes at a time.
The survey found, however, that some Europeans do not consider their neighbourhoods suitable for walking or cycling, potentially restricting opportunities for active travel.
Mînzatu said affordable sport and safe places to exercise should be available close to where people live, including for children from families unable to afford club fees, older people and those with disabilities.
Health
Congenital Infections Linked to Higher Risks of Autism and Intellectual Disability
Children born with certain infections acquired during pregnancy face substantially higher risks of autism and intellectual disability later in life, according to a study of more than 3.7 million people in Sweden.
Researchers found that children with congenital infections were about three times more likely to be diagnosed with autism and more than seven times more likely to receive a diagnosis of intellectual disability than those without such infections.
The findings suggest that infections transmitted from a pregnant woman to her foetus may have lasting effects on brain development, although the study identifies an association rather than proving that the infections directly cause autism or intellectual disability.
The research focused on TORCH infections, a group that includes syphilis, rubella, toxoplasmosis, cytomegalovirus and herpesvirus. These infections can cross the placenta and affect the developing foetus, potentially increasing the risk of miscarriage, stillbirth and other pregnancy complications.
“Although these congenital infections are rare, some of them can be prevented, which makes them important from a public health perspective,” said Reneé Gardner of the Department of Global Public Health at Karolinska Institutet, who contributed to the study.
The researchers examined people born in Sweden between 1987 and 2021 and followed them for up to 30 years. Among the 3.7 million participants, 975 had been diagnosed with a congenital TORCH infection.
Although congenital infections accounted for only a small proportion of autism cases across the population, the risk among affected children was considerably higher. The researchers estimated that about one in five children born with a TORCH infection could later develop autism.
The study also found elevated risks of intellectual disability across different levels of severity. The risk of severe to profound intellectual disability was as much as 30 times higher among children with a congenital infection than among those without one.
The researchers found evidence of an impact on educational outcomes even among people who were not diagnosed with autism or intellectual disability. A total of 420 participants with a TORCH infection showed poor school performance without receiving either diagnosis.
Congenital cytomegalovirus, or CMV, is the most common of these infections globally and affects roughly one in 150 newborns. Its burden is substantially greater in low- and middle-income countries.
The researchers said the findings highlight the importance of prevention, particularly in regions where these infections are more common. They pointed to vaccination programmes and other preventive measures as important tools for reducing congenital infections.
They also called for improved identification of affected newborns. Current screening systems, including those used in Sweden, may miss asymptomatic infections because universal screening for TORCH infections is not routinely carried out.
The authors said stronger screening and prevention strategies could help identify children at risk earlier and improve long-term support and care.
Health
AI Chatbots Make Faster, Less Nuanced Kidney Transplant Decisions Than Doctors
Artificial intelligence chatbots may make faster and more confident decisions than human doctors when determining which patient should receive a life-saving kidney transplant, but a new study found that the systems often rely on fewer factors and show less sensitivity to the ethical complexity of such choices.
Researchers from Penn State University in the United States compared decisions made by large language models (LLMs) with choices made by people in earlier studies on kidney allocation. The researchers presented AI models with hypothetical cases based on existing datasets in which human participants had previously chosen between two patients competing for a single available kidney.
The patients were described using characteristics including age, health and drinking habits. Both were considered eligible for the transplant, requiring the decision maker to determine which patient should receive the available organ.
The researchers tested the AI systems in several ways. Some scenarios focused on individual characteristics, while others combined several traits to examine how the models handled competing considerations. In some tests, participants and AI systems were also given the option of flipping a coin, allowing researchers to assess indecision as part of moral decision-making.
Human participants generally placed greater importance on age, often favouring younger patients over older patients. Many of the AI models, however, placed greater weight on lower alcohol consumption.
Hadi Hosseini, the study’s lead researcher at Penn State University, said the findings showed that AI chatbots can diverge from human values when weighing characteristics of patients.
The researchers found that human decisions tended to consider several factors together and were more sensitive to context. LLMs, by contrast, frequently focused on a single characteristic when making their choices.
Another difference involved uncertainty. Human participants were more likely to recognise that organ allocation can involve competing ethical considerations and that there may not be one objectively correct answer. AI models generally showed little hesitation and committed to one choice.
John Dickerson, chief executive officer of Mozilla.ai and a collaborator on the study, said humans recognise ambiguity when allocating scarce resources and use debate to shape how such decisions are made.
The findings come as AI systems are increasingly being used in healthcare for clinical workflows, diagnosis, treatment planning and decisions involving limited medical resources.
The researchers said kidney allocation presents a particularly important test because decisions over deceased-donor and living-donor organs involve medical, ethical and moral considerations.
Hosseini said the ethical stakes are high because decisions involving organ allocation can directly affect patients’ lives. He stressed that the study was not intended to encourage replacing professional medical judgment with AI.
Instead, the researchers said understanding how AI systems behave in high-stakes situations is becoming increasingly important as individuals, organisations and businesses use AI to make decisions or provide recommendations.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Home Improvement2 years agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
